{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:56:12Z","timestamp":1791226572802,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,4,22]],"date-time":"2013-04-22T00:00:00Z","timestamp":1366588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Sustained efficacy over three pollen seasons of pre\u2010 and co\u2010seasonal treatment with 300<jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content> 5\u2010grass pollen sublingual tablet has been demonstrated in adults with moderate\u2010severe grass pollen\u2010associated allergic rhinoconjunctivitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the efficacy of discontinuous treatment with 300<jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content> 5\u2010grass pollen sublingual tablet during the post\u2010treatment pollen season of this long\u2010term study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults aged 18\u201350, sensitized to grass pollen, with a history of allergic rhinoconjunctivitis for more than two pollen seasons, and a retrospective rhinoconjunctivitis total symptom score \u2265\u00a012 (0\u201318 scale), were randomized to receive Placebo or a 300<jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content> tablet daily beginning either 4\u00a0months (4M) or 2\u00a0months (2M) prior to each pollen season and continuing for its duration for three consecutive years. They were followed over the subsequent immunotherapy\u2010free pollen season. Post\u2010treatment efficacy was evaluated using the Average Adjusted Symptom Score (<jats:styled-content style=\"fixed-case\">AA<\/jats:styled-content>d<jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>, adjusting the Rhinoconjunctivitis Total Symptom Score for rescue medication usage) during the post\u2010treatment pollen period. Secondary endpoints included Average Rhinoconjunctivitis Total Symptom Score (<jats:styled-content style=\"fixed-case\">ARTSS<\/jats:styled-content>), Average Rescue Medication Score (<jats:styled-content style=\"fixed-case\">ARMS<\/jats:styled-content>), overall Rhinoconjunctivitis Quality of Life Questionnaire (<jats:styled-content style=\"fixed-case\">RQLQ<\/jats:styled-content>) score and safety evaluation. Efficacy variables were analysed using <jats:sc>ancova<\/jats:sc>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 435 patients contributed to the Year 4 efficacy analyses. The Least\u2010Squares (<jats:styled-content style=\"fixed-case\">LS<\/jats:styled-content>) mean differences (95% confidence interval) in <jats:styled-content style=\"fixed-case\">AA<\/jats:styled-content>d<jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content> between active treatment and Placebo over the fourth pollen period were \u22121.14 (\u22122.03; \u22120.26) (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0114) and \u22121.43 (\u22122.32; \u22120.53) (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0019) in the (4M) and (2M) groups, corresponding to \u221222.9% and \u221228.5% relative <jats:styled-content style=\"fixed-case\">LS<\/jats:styled-content> mean differences (vs. Placebo) respectively. The active groups also showed statistically significant differences compared to Placebo in <jats:styled-content style=\"fixed-case\">ARTSS<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> ARMS<\/jats:styled-content> and overall <jats:styled-content style=\"fixed-case\">RQLQ<\/jats:styled-content> score. No safety risk was identified during the post\u2010treatment period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Clinical Relevance<\/jats:title><jats:p>Pre\u2010 and co\u2010seasonal treatment with 300<jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content> 5\u2010grass pollen sublingual tablet administered discontinuously for three consecutive years is efficacious post\u2010treatment, safe and well tolerated. Benefits of treatment were meaningful to patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cea.12100","type":"journal-article","created":{"date-parts":[[2013,2,14]],"date-time":"2013-02-14T16:25:40Z","timestamp":1360859140000},"page":"568-577","source":"Crossref","is-referenced-by-count":83,"title":["Post\u2010treatment efficacy of discontinuous treatment with 300IR 5\u2010grass pollen sublingual tablet in adults with grass pollen\u2010induced allergic rhinoconjunctivitis"],"prefix":"10.1111","volume":"43","author":[{"given":"A.","family":"Didier","sequence":"first","affiliation":[{"name":"Respiratory Diseases Department Rangueil\u2010Larrey Hospital Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.\u2010J.","family":"Malling","sequence":"additional","affiliation":[{"name":"Allergy Clinic Gentofte University Hospital Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Worm","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Allergy Center Charit\u00e9, CCM Charit\u00e9 \u2010 Universit\u00e4tsmedizin Berlin Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Horak","sequence":"additional","affiliation":[{"name":"Allergy Center Vienna West Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sussman","sequence":"additional","affiliation":[{"name":"The University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Melac","sequence":"additional","affiliation":[{"name":"Global Clinical Development Stallergenes S.A. Antony France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Souli\u00e9","sequence":"additional","affiliation":[{"name":"Global Clinical Development Stallergenes S.A. Antony France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. K.","family":"Zeldin","sequence":"additional","affiliation":[{"name":"Global Clinical Development Stallergenes S.A. Antony France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,4,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.06.003"},{"key":"e_1_2_8_3_1","first-page":"1","volume-title":"WAO White Book on Allergy","author":"Pawankar R","year":"2011"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2007.28.2934"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.09.034"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2011.03804.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.09.037"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e32834cb994"},{"issue":"91","key":"e_1_2_8_9_1","first-page":"1","article-title":"Sub\u2010lingual immunotherapy: World Allergy Organization Position Paper 2009","volume":"64","author":"Canonica GW","year":"2009","journal-title":"Allergy"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.07.046"},{"issue":"160","key":"e_1_2_8_11_1","first-page":"e3","article-title":"Efficacy and safety of 5\u2010grass\u2010pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis","volume":"123","author":"Wahn U","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.06.022"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2011.03700.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70380-5"},{"key":"e_1_2_8_15_1","unstructured":"Committee for Medicinal Products for Human Use.Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP\/EWP\/18504\/2006.London:European Medicines Agency 2008."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.08.032"},{"key":"e_1_2_8_17_1","article-title":"Efficacy and safety of 2\u2010month pre\u2010seasonal and co\u2010seasonal treatment with a 5\u2010grass pollen allergen extract sublingual tablet","author":"Zeldin RK","year":"2013","journal-title":"Allergy Asthma Proc"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908123410702"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01011.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2002.1o3264.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01451.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.10.039"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.05.003"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.10.035"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.12.973"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcea.12100","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.12100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T15:58:21Z","timestamp":1697644701000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cea.12100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,22]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1111\/cea.12100"],"URL":"https:\/\/doi.org\/10.1111\/cea.12100","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,22]]}}}